MCID: DYS015
MIFTS: 52

Dysentery

Categories: Blood diseases, Gastrointestinal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Dysentery

MalaCards integrated aliases for Dysentery:

Name: Dysentery 11 43 14 16 71 75
Infectious Diarrhea 11 53 63

Classifications:



External Ids:

Disease Ontology 11 DOID:12384
ICD9CM 34 009.2
MeSH 43 D004403
SNOMED-CT 68 154268000
UMLS 71 C0013369

Summaries for Dysentery

PubMed Health : 63 Infectious diarrhea: Diarrhea is very common: In Germany, for instance, adults get it once a year on average, and it is even more common in children. It is usually caused by viruses, the most common of which are the highly contagious norovirus and rotavirus. Infectious diarrhea can also come from bacteria such as Salmonella or Campylobacter. In normal cases of diarrhea, you can usually just replace the fluids you lose and wait until the infection goes away. But more severe or longer lasting diarrhea needs to be treated because it can lead to the loss of dangerously high levels of fluid and salt, especially in young children and older people.

MalaCards based summary: Dysentery, also known as infectious diarrhea, is related to shigellosis and campylobacteriosis, and has symptoms including diarrhea An important gene associated with Dysentery is ALB (Albumin), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Loperamide and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and small intestine, and related phenotypes are homeostasis/metabolism and neoplasm

Disease Ontology: 11 An intestinal infectious disease that involves inflammation of the intestines, especially colon, due to chemical irritants, bacteria, protozoa, or parasitic worms, which results in severe diarrhea with passage of mucus and blood.

Wikipedia: 75 Dysentery (UK pronunciation: /ˈdɪsəntri/, US: /ˈdɪsəntɛri/), historically known as the bloody flux, is a... more...

Related Diseases for Dysentery

Diseases related to Dysentery via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 918)
# Related Disease Score Top Affiliating Genes
1 shigellosis 32.3 STX2 STX1A ST8SIA2 LTF IL1B IL1A
2 campylobacteriosis 32.0 STX2 STX1A ST8SIA2 IL10
3 amebiasis 31.8 TNF IL6 IL1B IL10 CXCL8 ALB
4 schistosomiasis 31.8 TNF IL1A IL10 CRP ALB
5 parasitic helminthiasis infectious disease 31.6 TNF IL6 IL1B IL10 CCR6 ALB
6 diarrhea 31.2 TTR TNF IL6 IL1B IL10 IFNA2
7 typhoid fever 31.2 TNF IL6 IL1B IL1A CRP CCR6
8 paratyphoid fever 31.1 TNF IL1B IL1A CRP
9 keratoconjunctivitis 31.0 TNF LTF IL1A ALB
10 epidemic typhus 30.9 IL10 CRP ALB
11 inflammatory bowel disease 1 30.8 TNF IL6 IL1B IL10 CCR6
12 trichuriasis 30.8 TNF IL10 CXCL8
13 cholera 30.8 TNF TF IL6 IL1B IL10 CXCL8
14 salmonellosis 30.7 TNF IL6 IL1B IL10 CXCL8 CCR6
15 enterocolitis 30.7 TNF IL6 IL10 CXCL8 CRP
16 reactive arthritis 30.6 TNF LTF HP CRP CCR6
17 hemolytic uremic syndrome, atypical 1 30.6 ST8SIA2 HP CRP ALB
18 viral hepatitis 30.5 IL6 IFNA2 CRP ALB
19 nutritional deficiency disease 30.5 TTR TF IL6 CRP CCR6 ALB
20 ulcerative colitis 30.5 TNF IL6 IL1B IL10 CXCL8 CRP
21 toxic megacolon 30.4 TNF CRP CCR6 ALB
22 protein-losing enteropathy 30.4 TTR CRP ALB
23 iron metabolism disease 30.4 TTR TF CRP
24 disseminated intravascular coagulation 30.4 TNF IL6 IL10 CRP
25 gastroenteritis 30.4 TNF IL6 IL1B IL10 IFNA2 CXCL8
26 cholecystitis 30.4 HP CRP ALB
27 intussusception 30.4 IL6 CRP ALB
28 gallbladder disease 30.4 IL6 CRP CCR6 ALB
29 acute kidney failure 30.3 IL6 HP ALB
30 sleeping sickness 30.3 TNF TF IL10 HP ALB
31 syphilis 30.3 TNF CRP CCR6 ALB
32 irritable bowel syndrome 30.3 TNF IL6 IL1B IL10 CXCL8 CRP
33 scarlet fever 30.3 TNF IL6 IL1B CRP ALB
34 tetanus 30.3 TNF IL6 IL1B IL1A IL10 CRP
35 alcohol dependence 30.2 TNF TF IL1B IL1A ALB
36 lactose intolerance 30.2 TNF IL6 IL10 CRP ALB
37 guillain-barre syndrome 30.2 TNF HP ALB
38 parotitis 30.2 LTF CRP ALB
39 appendicitis 30.2 TNF IL6 IL1B IL10 ENO2 CXCL8
40 cystitis 30.2 TNF IL6 CXCL8 CRP
41 colitis 30.2 TNF LTF IL6 IL1B IL10 CXCL8
42 abdominal tuberculosis 30.2 TNF CRP ALB
43 immunoglobulin alpha deficiency 30.2 IL10 HP CCR6
44 pleural empyema 30.2 IL6 CRP ALB
45 adult syndrome 30.2 TNF IL6 CRP
46 pasteurellosis 30.1 HP CXCL8 ALB
47 liver cirrhosis 30.1 TTR TNF TF IL6 HP ALB
48 acute diarrhea 30.1 STX2 STX1A ST8SIA2 IL10 CXCL8 CRP
49 angina pectoris 30.1 TNF IL6 CRP
50 bowel dysfunction 30.1 TNF LTF IL6 IL1B IL10 CRP

Comorbidity relations with Dysentery via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Dysentery:



Diseases related to Dysentery

Symptoms & Phenotypes for Dysentery

UMLS symptoms related to Dysentery:


diarrhea

GenomeRNAi Phenotypes related to Dysentery according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.14 ALB CCR6 CRP CXCL8 ENO2 HP
2 no effect GR00402-S-2 10.14 ALB CCR6 CRP HP IFNA2 IL10

MGI Mouse Phenotypes related to Dysentery:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 ALB CCR6 CRP HP IL10 IL1A
2 neoplasm MP:0002006 9.86 ALB HP IL10 IL1A IL1B IL6
3 cardiovascular system MP:0005385 9.7 ALB CCR6 CRP HP IL10 IL1A
4 immune system MP:0005387 9.4 ALB CCR6 CRP HP IFNA2 IL10

Drugs & Therapeutics for Dysentery

PubMed Health treatment related to Dysentery: 63

You lose fluids and electrolytes when you have diarrhea , so it is important to replace them. For acute , non-severe diarrhea you usually just need something like tea with sugar and some salted crackers. Foods that are gentle on the stomach is recommended too, such as rice, bananas or rusk bread. Some people also avoid coffee, fruit juices, sodas, alcohol and fatty foods to keep from irritating their bowel even more. Acute , non-severe diarrhea does not require special treatment in adults and teenagers. But it is a good idea for young children and older people, as well as people with more severe diarrhea, to replace fluids and electrolytes by using oral rehydration salts (electrolyte /glucose solutions) from the pharmacy. These are powders containing salts, minerals and glucose that can be dissolved in water. If these solutions are not available (for instance, while traveling) the following ingredients can be stirred into one liter of bottled or boiled water: Five tablespoons of sugar One and a half level tablespoons of salt One glass of packaged orange juice In addition to drinking fluids and using other treatments , foods or dietary supplements that have probiotic microorganisms (probiotics ) in them can help to make the diarrhea go away faster. Depending on how severe the symptoms are and how long they last, other treatments may be considered too: Drugs like loperamide or racecadotril can help to slow down the activity of the bowel and lower the number of times you need to go to the bathroom. Loperamide is not suitable for children under the age of twelve years, and racecadotril is prescription-only for children. Sometimes certain types of yeast tablets (Perenterol) are also recommended. These tablets are thought to help the body get rid of the germs faster and to support natural gut flora. Charcoal tablets dissolved in water can also be taken to relieve diarrhea symptoms. But there is a lack of good-quality research in this area so no conclusions can be drawn about the benefits and harms of these treatment options. Antibiotics are only an option if the infection is bacterial. They can't fight viruses .

Drugs for Dysentery (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Loperamide Approved Phase 4 53179-11-6 3955
2
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
3
Mebendazole Approved, Vet_approved Phase 4 31431-39-7 4030
4
Piperazine Approved, Vet_approved Phase 4 110-85-0 4837
5
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1, 93107-08-5 2764
6
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
7 Antidiarrheals Phase 4
8 Antimitotic Agents Phase 4
9 Anthelmintics Phase 4
10 Antiparasitic Agents Phase 4
11 Tubulin Modulators Phase 4
12 Citrate Phase 4
13 Piperazine citrate Phase 4
14 DMP 777 Phase 4 157341-41-8
15 Anti-Retroviral Agents Phase 4
16 Fluoroquinolones Phase 4
17
Rifamycin Approved, Investigational Phase 3 6998-60-3 6324616
18
Zinc cation Approved, Experimental, Investigational Phase 3 7440-66-6, 23713-49-7 32051
19
Nitazoxanide Approved, Investigational, Vet_approved Phase 3 55981-09-4 41684
20
Aluminium phosphate Approved, Investigational Phase 3 7784-30-7
21 Immunologic Factors Phase 3
22 Antirheumatic Agents Phase 3
23 Cytochrome P-450 Enzyme Inhibitors Phase 3
24 Immunoglobulins Phase 3
25 Antibodies Phase 3
26 Trace Elements Phase 3
27 Micronutrients Phase 3
28
Rifamycins Phase 3 422447
29
Auranofin Approved, Investigational Phase 2 34031-32-8 6918453 16667669 70788951
30
Histamine Approved, Investigational Phase 2 51-45-6 774
31
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
32
Azithromycin Approved Phase 2 83905-01-5 447043
33
Ceftriaxone Approved Phase 2 73384-59-5 5479530
34
Inulin Approved, Investigational, Nutraceutical Phase 1, Phase 2 9005-80-5 24763
35
Butyric Acid Experimental, Investigational Phase 2 107-92-6 264
36 Complement System Proteins Phase 1, Phase 2
37 Complement Factor H Phase 1, Phase 2
38 Immunosuppressive Agents Phase 1, Phase 2
39 Neurotransmitter Agents Phase 2
40
Histamine phosphate Phase 2 51-74-1 134614
41 Histamine Antagonists Phase 2
42 Acidophilus Phase 1, Phase 2
43 Anti-Ulcer Agents Phase 2
44 Adjuvants, Immunologic Phase 2
45 Antacids Phase 2
46 Antibiotics, Antitubercular Phase 2
47 Cephalosporins Phase 2
48 beta-Lactams Phase 2
49 Lactams Phase 2
50 Pharmaceutical Solutions Phase 2

Interventional clinical trials:

(show top 50) (show all 92)
# Name Status NCT ID Phase Drugs
1 Introduction of New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Management of Diarrhoeal Diseases - A Phase IV Surveillance Study Completed NCT00490932 Phase 4 Hypo-osmolar ORS
2 Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population Completed NCT02385058 Phase 4 Mebendazole;Quinfamide;Placebo
3 Rifaximin in Standard Three-Day Dosing With and Without the Antimotility Drug, Loperamide, in the Treatment of Travelers' Diarrhea Completed NCT00292344 Phase 4 Rifaximin and loperamide
4 A Phase 4 Open Label Study to Assess the Safety and Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in People Living With HIV/AIDS (PLWHA) With Non-Infectious Diarrhea Completed NCT04192487 Phase 4 Crofelemer delayed-release tablets 125mg
5 An Open Label Randomised Controlled Trial of Azithromycin Versus Ciprofloxacin for the Treatment of Children Hospitalised With Dysentery in Ho Chi Minh City, Vietnam Recruiting NCT03854929 Phase 4 Ciprofloxacin;Azithromycin
6 A Parallel, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Probiotic Formula in the Prevention of Traveler's Diarrhea Terminated NCT01005849 Phase 4
7 Single Daily Dose Rifaximin vs. Standard Thrice Daily Dosing for the 3-Day Treatment of Travelers' Diarrhea Withdrawn NCT00875875 Phase 4 Rifaximin
8 Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni Completed NCT02280044 Phase 2, Phase 3
9 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rifamycin SV MMX for the Treatment of Traveler's Diarrhea Completed NCT01142089 Phase 3 Placebo;Rifamycin SV MMX
10 A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System Completed NCT00993681 Phase 3
11 Effect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following recoveryEffect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following Recovery Completed NCT00321126 Phase 3 Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.
12 Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Children Completed NCT00366730 Phase 3 Nitazoxanide
13 Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Tablets in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Adults and Adolescents Completed NCT00366236 Phase 3 Nitazoxanide
14 Phase 3 Study (Safety, Immunogenicity and Efficacy) of Improved Shigella Conjugate Vaccines in 1-4 Year Olds in Israel Completed NCT00368316 Phase 3
15 A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX® 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Travellers Completed NCT01208922 Phase 3 Rifamycin SV-MMX®;Ciprofloxacin
16 A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years Recruiting NCT05156528 Phase 3
17 A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center, Therapeutic Equivalence Study to Compare Rifaximin 200 mg Tablets (Sandoz GmbH) to Xifaxan® 200 mg Tablets (Salix Pharmaceuticals, Inc.) and Placebo in Patients With Travelers' Diarrhea Terminated NCT02920242 Phase 3 Rifaximin (Sandoz GmbH) tablet;Rifaximin (Xifaxan);Placebo
18 Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea Withdrawn NCT02736539 Phase 3 CBS 2004 (galacto-oligosaccharides);Placebo
19 A Randomized, Blinded, Single-center, Parallel Controlled , Phase Ⅱ Clinical Trial to Evaluate Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged From 3 Months to 5 Years Old Completed NCT04865497 Phase 2
20 Phase IIa Randomized, Single-Blinded, Placebo-Controlled Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa Completed NCT02736968 Phase 2 Auranofin
21 Efficacy, Safety and Immunogenicity of GVGH Shigella Sonnei Vaccine (1790GAHB) in a Human Challenge Study of Healthy Non-immune Adults Completed NCT03527173 Phase 2 Placebo
22 Safety, Immunogenicity, and Efficacy Studies of WRSS1, a Live Attenuated Shigella Sonnei Vaccine Candidate, in Healthy Thai Adults Completed NCT01080716 Phase 1, Phase 2
23 A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis Completed NCT02676895 Phase 2
24 Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a Completed NCT02646371 Phase 2
25 Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection Completed NCT00485134 Phase 1, Phase 2
26 Therapeutic Induction of Endogenous Antibiotics for Improved Recovery in Shigellosis Completed NCT00800930 Phase 2
27 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults Completed NCT00751777 Phase 2
28 Exploratory Study to Evaluate the Effect of L-isoleucine Supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children and in Inducing Innate Immunity Completed NCT01034228 Phase 2
29 Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants Completed NCT04056117 Phase 1, Phase 2
30 Probiotics for Infectious Diarrhea in Children in South India Completed NCT01130792 Phase 1, Phase 2
31 A Phase Two, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System in Travelers to Asia Completed NCT01040325 Phase 2
32 A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of Two Doses 10^5 and 10^7 CFU of SC599 Oral Vaccine, a Live Attenuated Shigella Dysenteriae 1 Vaccine Strain in Healthy Human Adult Volunteers Completed NCT00210288 Phase 2
33 Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea. A Pilot, Dose Finding, Double-blind, Randomized, Multicentre Study Completed NCT03447821 Phase 2 400 mg Rifamycin SV dosage;800 mg Rifamycin SV dosage;1200 mg Rifamycin SV dosage
34 Phase 2b Study of the Safety, Immunogenicity, and Efficacy of a Monovalent Synthetic Carbohydrate-based Conjugate Vaccine (SF2a-TT15) for Protection Against Shigella Flexneri 2a Experimental Infection Recruiting NCT04078022 Phase 2
35 A Phase 2a Age Descending Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a in Adults, Children, and Infant Target Population in Endemic Countries. Active, not recruiting NCT04602975 Phase 2
36 A Double-Blind Placebo Controlled Phase 2 Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of a Live-Attenuated Shigella Sonnei Vaccine, WRSs2 and Determine Its Efficacy in a Challenge Model of S. Sonnei 53G in Healthy Adults Not yet recruiting NCT04242264 Phase 2
37 A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis With Shigella Flexneri 2a Strain Not yet recruiting NCT05182749 Phase 1, Phase 2
38 Double Blind, Multi-center Study to Evaluate the Safety and Efficacy of 100 mg Twice Daily Rifamycin SV MMX® Added to Standard ORT Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years Not yet recruiting NCT04026984 Phase 2 Rifamycin SV-MMX;Placebo
39 Double Blind Study to Evaluate the Safety and Efficacy of 400 mg Twice Daily Rifamycin SV MMX® Added to Standard Oral Rehydration Therapy (ORT) Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 12 to 17 Years Not yet recruiting NCT04027894 Phase 2 Rifamycin SV MMX;Placebo to Rifamycin SV-MMX
40 Tebipenem-pivoxil as an Alternative to Ceftriaxone for Clinically Non-responding Children With Shigellosis: a Randomized Non-inferiority Trial Not yet recruiting NCT05121974 Phase 2 Tebipenem Pivoxil;Azithromycin;Ceftriaxon
41 Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIa Vaccination Study Terminated NCT00866476 Phase 2
42 Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIb Challenge Study Terminated NCT00866242 Phase 2
43 A Phase 2a/2b, Randomized, Double-blinded, Placebo-controlled, Trial to Assess the Safety, Immunogenicity and Efficacy of Inactivated Shigella Flexneri 2a Whole Cell (Sf2aWC) Vaccine Administered With and Without Double Mutant E. Coli Heat Labile Toxin (dmLT) in Healthy Adult Subjects Withdrawn NCT03038243 Phase 2
44 A Single-center, Open, Phase I Clinical Trial to Evaluate Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months Completed NCT03561181 Phase 1
45 A Phase I Dose Escalation Study to Assess the Safety and Immunogenicity of the SF2a-TT15 Conjugate Vaccine Against S. Flexneri 2a in Healthy Adult Volunteers Completed NCT02797236 Phase 1
46 A Phase 1, Open Label, Non-randomized, Single Center Study to Evaluate the Safety and Immunogenicity of 1 Booster Vaccination With (GVGH Shigella Sonnei 1790GAHB) Vaccine Administered Intramuscularly in Healthy Adults Previously Primed With Three Doses of the Same Vaccine in Study H03_01TP Compared to 1 Vaccination With (1790GAHB) Administered Intramuscularly Either to Subjects Who Received Placebo in the H03_01TP Study or naïve Subjects Who Were Not Part of H03_01TP Study Completed NCT03089879 Phase 1
47 A Phase 1 Open-label, Dose Escalating Study of Artificial Shigella Flexneri 2a InvaplexAR Administered Intranasally to Healthy, Adult Volunteers to Evaluate Safety and Immunogenicity Completed NCT02445963 Phase 1
48 An Open Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Auranofin Following Oral Dose Administration for 7 Days to Healthy Subjects Completed NCT02089048 Phase 1 Auranofin
49 A Phase 1, Randomized, Observer Blinded, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Intramuscularly in Healthy Adults. Completed NCT02017899 Phase 1
50 A Phase 1, Randomized, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults. Completed NCT02034500 Phase 1

Search NIH Clinical Center for Dysentery

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ciprofloxacin
Scopolamine
Scopolamine Hydrobromide

Cochrane evidence based reviews: dysentery

Genetic Tests for Dysentery

Anatomical Context for Dysentery

Organs/tissues related to Dysentery:

MalaCards : Colon, Liver, Small Intestine, Neutrophil, Lymph Node, Skin, Bone Marrow

Publications for Dysentery

Articles related to Dysentery:

(show top 50) (show all 8927)
# Title Authors PMID Year
1
Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. 53 62
19028207 2008
2
Antibiotics for the empirical treatment of acute infectious diarrhea in children. 53 62
17568855 2006
3
Gallic acid alleviates gastric precancerous lesions through inhibition of epithelial mesenchymal transition via Wnt/β-catenin signaling pathway. 62
36328204 2023
4
Botany, ethnopharmacology, phytochemistry and pharmacology of Erodii Herba Geranii Herba-An review. 62
36341816 2023
5
Deciphering the underlying wound healing mechanisms of Streptocaulon juventas (Lour.) Merr. by integrating network pharmacology, transcriptomics, and experimental validation. 62
36336222 2023
6
Citrate and hydroxycinnamate derivatives from Mume Fructus protect LPS-injured intestinal epithelial cells by regulating the FAK/PI3K/AKT signaling pathway. 62
36270558 2023
7
A comparative study of Liandan Xiaoyan Formula metabolic profiles in control and colitis rats by UPLC-Q-TOF-MS combined with chemometrics. 62
36332331 2023
8
A review on the traditional uses, phytochemistry, and pharmacology of the genus Veronicastrum (Plantaginaceae). 62
36108894 2023
9
Geographical variation in the effect of ambient temperature on infectious diarrhea among children under 5 years. 62
36208789 2023
10
In vitro evaluation of gentamicin activity against Spanish field isolates of Brachyspira hyodysenteriae. 62
36451249 2022
11
Discovery of metabolic markers for the discrimination of Helwingia species based on bioactivity evaluation, plant metabolomics, and network pharmacology. 62
36195983 2022
12
Bacteriophages: An Alternative to Combat Antibiotic Resistance? 62
36468950 2022
13
Computational characterization of homologous ligands binding to a deep hydrophobic pocket in Shigella flexneri pilot protein MxiM. 62
35871311 2022
14
Hypothetical proteins play a role in stage conversion, virulence, and the stress response in the Entamoeba species. 62
36309065 2022
15
Could a Shigella vaccine impact long-term health outcomes?: Summary report of an expert meeting to inform a Shigella vaccine public health value proposition, March 24 and 29, 2021. 62
36237199 2022
16
Sleep duration prior to an enterotoxigenic Escherichia coli challenge predicts diarrhea severity during infection. 62
36240601 2022
17
Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management. 62
36460884 2022
18
Colonic innate immune defenses and microbiota alterations in acute swine dysentery. 62
36371065 2022
19
The size of the susceptible pool differentiates climate effects on seasonal epidemics of bacillary dysentery. 62
36455742 2022
20
Impatiens balsamina: An updated review on the ethnobotanical uses, phytochemistry, and pharmacological activity. 62
36436713 2022
21
Alternanthera sessilis: Uncovering the nutritional and medicinal values of an edible weed. 62
35973630 2022
22
Diagnostic testing practices for diarrhoeal cases in South African public hospitals. 62
36352368 2022
23
Polysaccharides from Tetrastigma Hemsleyanum Diels et Gilg attenuate LPS-induced acute lung injury by modulating TLR4/COX-2/NF-κB signaling pathway. 62
36182735 2022
24
Chemical constituents from the seed husks of Oryza sativa L. 62
34963398 2022
25
GC-MS Analysis of Bioactive Compounds of Flower Extracts of Calycopteris floribunda Lam.: A Multi Potent Medicinal Plant. 62
35689756 2022
26
Multi-omics analysis to characterize molecular adaptation of Entamoeba histolytica during serum stress. 62
36066285 2022
27
Cysteine-Dependent Conformational Heterogeneity of Shigella flexneri Autotransporter IcsA and Implications of Its Function. 62
36374106 2022
28
A systematic review of tools for predicting complications in patients with acute infectious diarrhea. 62
36469970 2022
29
Occurrence and Characteristics of Escherichia albertii in Wild Birds and Poultry Flocks in Switzerland. 62
36422334 2022
30
Common Etiological Agents in Adult Patients with Gastroenteritis from Central Iran. 62
36130139 2022
31
Analysis of the epidemiological characteristics between 2004 and 2017 and prediction of the changing pattern of other infectious diarrhea (OID) under COVID-19 in China. 62
36281122 2022
32
Three metal complexes with a pyridyl Schiff base: cytotoxicity, migration and mechanism of apoptosis. 62
36111968 2022
33
Bacteroides thetaiotaomicron Outer Membrane Vesicles Modulate Virulence of Shigella flexneri. 62
36102517 2022
34
Quality consistency evaluation on three species of North Patrininae herba by high-performance liquid chromatography coupled with electrospray ion trap time-of-flight mass spectrometry and network pharmacology approaches. 62
35988143 2022
35
Dynamics of the Gut Microbiome in Shigella-Infected Children during the First Two Years of Life. 62
36121169 2022
36
[Evaluation of the Methods Used for the Detection of Entamoeba histolytica in Stool Samples of Patients with Diarrhea]. 62
36458714 2022
37
Tapinanthus species: A review of botany and biology, secondary metabolites, ethnomedical uses, current pharmacology and toxicology. 62
35714877 2022
38
Morinda umbellata active fraction inhibits lipopolysaccharide induced proinflammatory cytokines by downregulating NF-κB activation. 62
36337241 2022
39
Isolation and Genetic Characterization of a Bovine Coronavirus KBR-1 Strain from Calf Feces in South Korea. 62
36366474 2022
40
Uncovering the mechanism of Huanglian-Wuzhuyu herb pair in treating nonalcoholic steatohepatitis based on network pharmacology and experimental validation. 62
35644437 2022
41
Holm Oak (Quercus ilex subsp. ballota (Desf.) Samp.) Bark Aqueous Ammonia Extract for the Control of Invasive Forest Pathogens. 62
36233184 2022
42
The Therapeutic Efficacy of Punica granatum and Its Bioactive Constituents with Special Reference to Photodynamic Therapy. 62
36365273 2022
43
Hypericumsampsonii attenuates inflammation in mice with ulcerative colitis via regulation of PDE4/PKA/CREB signaling pathway. 62
35688258 2022
44
Choline, DHA, and Diarrheal Disease Associated with Growth Faltering in a Case-Control Study. 62
36204326 2022
45
Clostridium difficile colitis portends poor outcomes in lower extremity orthopaedic trauma surgery. 62
36002345 2022
46
[Analysis of epidemiological characteristics of bacillary dysentery with multiple-onset in Henan Province from 2005 to 2020]. 62
36274616 2022
47
First report and genomic characterization of a bovine-like coronavirus causing enteric infection in an odd-toed non-ruminant species (Indonesian tapir, Acrocodia indica) during an outbreak of winter dysentery in a zoo. 62
34427399 2022
48
In Vitro Screening of Non-Antibiotic Components to Mitigate Intestinal Lesions Caused by Brachyspira hyodysenteriae, Lawsonia intracellularis and Salmonella enterica Serovar Typhimurium. 62
36139216 2022
49
Elucidation of Key Interactions between VirF and the virB Promoter in Shigella flexneri Using E. coli MarA- and GadX-Based Homology Models and In Vitro Analysis of the DNA-Binding Domains of VirF and MarA. 62
36040161 2022
50
Study on the mechanism of Huangqin Decoction on rats with ulcerative colitis of damp-heat type base on mtDNA, TLR4, p-PI3K, p-Akt protein expression and microbiota. 62
35568112 2022

Variations for Dysentery

Expression for Dysentery

Search GEO for disease gene expression data for Dysentery.

Pathways for Dysentery

Pathways related to Dysentery according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 TTR TNF STX1A LTF IL6 IL1B
2
Show member pathways
13.39 TNF IL6 IL1B IL1A IL10 CXCL8
3
Show member pathways
13.34 TNF STX1A IL6 IL1B IL1A IL10
4
Show member pathways
13.3 TNF IL6 IL1B IL1A IL10 CXCL8
5
Show member pathways
12.87 TNF IL6 IL1B IL1A IFNA2 CXCL8
6
Show member pathways
12.66 CXCL8 IFNA2 IL10 IL1A IL1B IL6
7
Show member pathways
12.63 TNF IL6 IL1B IL1A CXCL8
8
Show member pathways
12.54 TNF IL6 IL1B IFNA2 CXCL8
9
Show member pathways
12.44 CXCL8 IL1A IL1B IL6 TNF
10
Show member pathways
12.35 TNF IL6 IL1B IL1A CXCL8
11 12.13 IL10 IL1A IL1B IL6 TNF
12 12.03 IFNA2 IL10 IL6 TNF
13 12.03 TNF IL6 IL1B IL1A CXCL8
14 11.98 IL6 IL1B IL1A CXCL8
15
Show member pathways
11.95 IL10 IL1B IL6 TNF
16 11.92 IL6 IL10 CXCL8 CCR6
17 11.9 TNF IL1B IL1A IL10 CXCL8
18 11.88 CXCL8 IL10 IL1A IL1B IL6 TNF
19 11.83 TNF IL1B IL10 CCR6
20 11.78 CXCL8 IFNA2 IL1B IL6 TNF
21 11.77 TNF IL6 IL10 CRP
22
Show member pathways
11.76 IL6 CXCL8 CRP
23 11.76 TNF IL6 IL1B IL10 IFNA2
24 11.72 TNF IL6 IL1B CXCL8
25 11.71 IL6 IL10 CXCL8
26 11.7 TNF TF IL6 IL1B IL1A IL10
27
Show member pathways
11.68 TNF IL6 IL1A IL10
28
Show member pathways
11.65 TNF IL6 IL1B IL1A CXCL8
29 11.62 TNF IL6 IL1A IL10 CXCL8
30 11.6 TNF IL6 IFNA2 CXCL8
31 11.59 TNF IL6 IL1B IL1A IL10
32 11.58 TNF IL1A IL10
33 11.57 TNF IL10 CXCL8
34 11.53 TNF IL6 IL1B IL1A
35 11.52 IL1A IL6 TNF
36
Show member pathways
11.49 TNF STX1A IL1B
37 11.36 TNF IL6 IL1B
38 11.33 TNF IL6 IL1B CXCL8
39 11.26 TNF IL6 IL10 CXCL8
40 11.26 TNF IL6 IL1B IL1A IL10
41 11.13 IL6 IL1B IL10
42 11.12 TNF IL6 IL1B IL1A IL10
43 11.06 TNF IL6 CXCL8 CRP
44 11.05 TNF IL6 IL1B IL1A IL10 CXCL8
45 11 TNF IL6 IL1B IL1A CXCL8
46 10.77 TNF IL6 IL1B IL1A IL10 CXCL8
47 10.7 IL6 CXCL8
48
Show member pathways
10.43 TNF IL6 CXCL8

GO Terms for Dysentery

Cellular components related to Dysentery according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.1 ALB CRP CXCL8 HP IFNA2 IL10
2 extracellular space GO:0005615 9.8 ALB CRP CXCL8 ENO2 HP IFNA2
3 recycling endosome GO:0055037 9.76 TNF TF ST8SIA2 LTF

Biological processes related to Dysentery according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell population proliferation GO:0008285 10.35 TNF IL6 IL1B IL1A IL10 CXCL8
2 inflammatory response GO:0006954 10.25 CRP CXCL8 IFNA2 IL1A IL1B IL6
3 defense response to Gram-positive bacterium GO:0050830 10.24 CRP IL1B IL6 TNF
4 positive regulation of DNA-binding transcription factor activity GO:0051091 10.23 TNF IL6 IL1B IL10
5 positive regulation of interleukin-6 production GO:0032755 10.19 IL1A IL1B IL6 TNF
6 cytokine-mediated signaling pathway GO:0019221 10.18 IFNA2 IL1A IL1B IL1RAPL2 IL6
7 immune response GO:0006955 10.16 TNF IL6 IL1B IL1A IL10 CXCL8
8 retina homeostasis GO:0001895 10.13 TF LTF ALB
9 acute-phase response GO:0006953 10.11 IL6 HP CRP
10 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.1 IL10 IL6 TNF
11 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 10.09 IL1A IL1B TNF
12 positive regulation of mitotic nuclear division GO:0045840 10.08 TNF IL1B IL1A
13 positive regulation of chemokine production GO:0032722 10.06 TNF IL6 IL1B
14 liver regeneration GO:0097421 10.06 TNF IL6 IL10
15 positive regulation of vascular endothelial growth factor production GO:0010575 10.05 IL6 IL1B IL1A
16 positive regulation of cytokine production GO:0001819 10.05 TNF IL1B IL1A IL10
17 defense response GO:0006952 10.03 TNF IFNA2 HP CXCL8
18 negative regulation of neurogenesis GO:0050768 10.02 IL1B IL6 TNF
19 positive regulation of glial cell proliferation GO:0060252 9.97 TNF IL6 IL1B
20 regulation of insulin secretion GO:0050796 9.97 TNF STX1A IL6 IL1B
21 negative regulation of cytokine production involved in immune response GO:0002719 9.96 TNF IL10
22 positive regulation of fever generation GO:0031622 9.95 TNF IL1B
23 acute inflammatory response GO:0002526 9.92 TNF IL1A HP
24 sequestering of triglyceride GO:0030730 9.91 TNF IL1B
25 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.91 TNF IL1B IL10
26 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.87 TNF IL1B
27 fever generation GO:0001660 9.86 IL1B IL1A
28 chronic inflammatory response to antigenic stimulus GO:0002439 9.84 TNF IL10
29 positive regulation of neuroinflammatory response GO:0150078 9.8 TNF IL6 IL1B
30 negative regulation of lipid storage GO:0010888 9.73 TNF IL6 CRP
31 cellular response to lipopolysaccharide GO:0071222 9.7 TNF IL6 IL1B IL1A IL10 CXCL8
32 vascular endothelial growth factor production GO:0010573 9.63 IL1B IL6 TNF
33 humoral immune response GO:0006959 9.32 TNF LTF IL6 IFNA2 CCR6

Molecular functions related to Dysentery according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.44 TNF IL6 IL1B IL1A IL10 IFNA2

Sources for Dysentery

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....